Forecasts indicate that the Fibroblast Activation Protein Inhibitor Market is entering a transformative phase, with substantial market share shifts expected by 2035. The market, valued at $3.144 billion in 2024, is anticipated to expand to approximately $8.722 billion over the forecast period. This growth represents a compound annual growth rate (CAGR) of 9.72%, reflecting the increasing demand...